Cocrystal Pharma financials
$1.12−7.44%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q3 '24 Sep 30 | Q2 '24 Jun 30 | Q1 '24 Mar 31 | Q4 '23 Dec 31 | Q3 '23 Sep 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $105.0K | $225.0K | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross profit | $105.0K | $225.0K | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross margin | 100.0% | 100.0% | — | — | — | — | — | — | — | — | — | — |
| Operating income | -$3.2M | -$2.4M | -$2.5M | -$2.1M | -$2.1M | -$2.3M | -$3.2M | -$5.0M | -$5.4M | -$4.2M | -$4.7M | -$4.4M |
| Net income | -$3.2M | -$2.3M | -$2.4M | -$2.0M | -$2.1M | -$2.3M | -$3.3M | -$4.9M | -$5.3M | -$4.0M | -$4.5M | -$4.2M |
| Net margin | −3013.3% | −1021.8% | — | — | — | — | — | — | — | — | — | — |
| Diluted EPS | $-0.23 | $-0.17 | $-0.18 | $-0.19 | $-0.20 | $-0.23 | $-0.32 | $-0.49 | $-0.53 | $-0.39 | $-0.44 | $-0.41 |
| EBITDA | -$3.2M | -$2.3M | -$2.5M | -$2.1M | -$2.1M | -$2.3M | -$3.2M | -$5.0M | -$5.4M | -$4.1M | -$3.0M | -$6.0M |
| Operating cash flow | -$2.5M | -$2.3M | -$1.7M | -$1.4M | -$2.2M | -$2.9M | -$3.2M | -$5.1M | -$3.7M | -$4.5M | -$3.3M | -$2.7M |
| Free cash flow | -$2.5M | -$2.3M | -$1.7M | -$1.4M | -$2.2M | -$2.9M | -$3.2M | -$5.1M | -$3.7M | -$4.5M | -$3.4M | -$2.7M |
| Diluted shares | 13.8M | 13.8M | 13.8M | 11.0M | 10.2M | 10.2M | 10.2M | 10.2M | 10.2M | 10.2M | 10.2M | 10.2M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $2.2M | $4.7M | $7.0M | $7.7M | $4.8M | $6.9M |
| Short-term investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total assets | $4.6M | $7.4M | $9.7M | $10.4M | $8.5M | $10.7M |
| Total liabilities | $3.6M | $3.3M | $3.4M | $2.8M | $3.2M | $3.4M |
| Shareholders' equity | $1.0M | $4.1M | $6.3M | $7.7M | $5.3M | $7.3M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology